Literature DB >> 17333526

What is the best predictor of postoperative erectile function in patients who will undergo coronary artery bypass surgery?

Fatih Hizli1, Burak Işler, Zeki Güneş, M Ali Ozatik, Ferhat Berkmen.   

Abstract

PURPOSE: The aim of this prospective study was to evaluate the impact of extracorporeal circulation and cross clamping period on erectile function in patients undergoing coronary artery bypass surgery (CABS).
MATERIALS AND METHODS: A total of 50 patients undergoing CABS were evaluated in this prospective study. Before and 6-12 months after the CABS, patients were interviewed for erectile dysfunction (ED) using the International Index of Erectile Function (IIEF). Scoring the IIEF domain of erectile function allowed the classification of each patient as having no (26-30), mild (17-25), moderate (11-16) or severe (0-10) ED. Patients with normal, mild and moderate ED score were designated as group A, B and C, respectively. Patients were classified in 2 groups to evaluate the impact of extracorporeal circulation and cross clamping period on erectile function in patients undergoing CABS. Patients who had no change in ED score in group A and patients who had recovery in group B were included in group1. Patients who had impaired ED score in group A and group B were included in group 2. All patients were also interviewed for sociodemographic and relevant medical history. Sociodemographic data were age, job, marital status, alcohol, narcotic and smoking habit. Medical risk factors were diabetes, hypertension and psychiatric disorders.
RESULTS: The mean age of patients included in the study were 46,6 (range 31-55). After the operation, 3 (7.5%) of 41 patients in group A had moderate, 1 (2.5%) had mild and 37 (90%) had no change in ED score. In group B, 2 (28%) of 7 patients had moderate, 4 (57%) had recovery in ED score, 1 had no change in ED score. There were only 2 patients in group C and 1 had severe, the other one had mild ED after the operation. The mean operation period was 234.8 m inutes in group 1 and 280 min in group 2. Cross clamping period and extracorporeal circulation of patients in group 1 and 2 were 33.2, 41.6 min and 54.7, 64.6 min, respectively. The groups were not statistically different with regard to mean operation, cross clamping and extracorporeal circulation period.
CONCLUSION: Preoperative erectile function seems to be the best predictor of postoperative erectile function in patients who will undergo CABS.

Entities:  

Mesh:

Year:  2007        PMID: 17333526     DOI: 10.1007/s11255-006-9118-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  18 in total

1.  Arteriographically determined occlusive disease within the hypogastric-cavernous bed in impotent patients following blunt perineal and pelvic trauma.

Authors:  F J Levine; A J Greenfield; I Goldstein
Journal:  J Urol       Date:  1990-11       Impact factor: 7.450

Review 2.  Cigarette smoking, hypertension and erectile dysfunction.

Authors:  A Ledda
Journal:  Curr Med Res Opin       Date:  2000       Impact factor: 2.580

3.  Erectile dysfunction due to atherosclerotic vascular disease: the development of an animal model.

Authors:  K M Azadzoi; I Goldstein
Journal:  J Urol       Date:  1992-06       Impact factor: 7.450

4.  Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

Authors:  M Braun; G Wassmer; T Klotz; B Reifenrath; M Mathers; U Engelmann
Journal:  Int J Impot Res       Date:  2000-12       Impact factor: 2.896

5.  Sexual activity after coronary bypass surgery.

Authors:  C Papadopoulos; S I Shelley; M Piccolo; C Beaumont; L Barnett
Journal:  Chest       Date:  1986-11       Impact factor: 9.410

6.  Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel.

Authors:  R DeBusk; Y Drory; I Goldstein; G Jackson; S Kaul; S E Kimmel; J B Kostis; R A Kloner; M Lakin; C M Meston; M Mittleman; J E Muller; H Padma-Nathan; R C Rosen; R A Stein; R Zusman
Journal:  Am J Cardiol       Date:  2000-07-20       Impact factor: 2.778

7.  Frequency and determinants of erectile dysfunction in Italy.

Authors:  F Parazzini; F Menchini Fabris; A Bortolotti; A Calabrò; L Chatenoud; E Colli; M Landoni; M Lavezzari; P Turchi; A Sessa; V Mirone
Journal:  Eur Urol       Date:  2000-01       Impact factor: 20.096

8.  Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease.

Authors:  Francesco Montorsi; Alberto Briganti; Andrea Salonia; Patrizio Rigatti; Alberto Margonato; Andrea Macchi; Stefano Galli; Paolo M Ravagnani; Piero Montorsi
Journal:  Eur Urol       Date:  2003-09       Impact factor: 20.096

9.  Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men.

Authors:  R Virag; P Bouilly; D Frydman
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

10.  Arterial disease as a cause of impotence.

Authors:  V Michal
Journal:  Clin Endocrinol Metab       Date:  1982-11
View more
  3 in total

1.  Erectile dysfunction in stroke patients: a multifactorial problem with important psychosocial consequences.

Authors:  Kosmas I Paraskevas; Nikolaos Bessias; Polyvios Pavlidis; Dimitrios Maras; Theofanis T Papas; Christos D Gekas; Vassilios Andrikopoulos
Journal:  Int Urol Nephrol       Date:  2008-08-06       Impact factor: 2.370

2.  Erectile dysfunction: a warning sign of silent vascular disease.

Authors:  Kosmas I Paraskevas; Sotirios A Koupidis; Dimitri P Mikhailidis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2009-12       Impact factor: 2.370

3.  Nebivolol compared with metoprolol for erectile function in males undergoing coronary artery bypass graft.

Authors:  Mustafa Aldemir; İbrahim Keleş; Mustafa Karalar; Evren Tecer; Fahri Adalı; Mehmet Bilgehan Pektaş; Ali İhsan Parlar; Osman Tansel Darçın
Journal:  Anatol J Cardiol       Date:  2015-02-11       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.